Objective: The purpose of the study was to determine the neonatal illicit drug screening practices of Iowa birthing hospitals.
Introduction
Drug endangerment of children either via in utero exposure or postnatal exposure is a provocative public health issue because of the associated medical, social, and psychological consequences. Being able to identify children who have been exposed to illicit drugs in utero became more of an issue in the mid to late 1980s with the rise of crack cocaine use in the United States. As illicit drug use has reached epidemic proportions, offering services to pregnant women addicted to drugs and protecting the well being of the unborn child and offspring have become a serious challenge for health professionals and social services. 1 One study reported that 5.5% of women use an illicit drug and 18.8% of women drink alcohol at some point during their pregnancy. 2 Other studies conducted at urban teaching hospitals have found maternal illicit drug use during pregnancy to range from 10 to 45% of all births. 1, 3, 4 If early intervention is not accomplished, infants often fall victim to further drug exposure, child abuse and neglect, and domestic violence during their childhood, as the majority of women who have stopped using illicit drugs during pregnancy relapse shortly after delivery. 5 Early intervention on the other hand can prevent such exposure for children and help them develop completely normally in terms of intellectual, social, emotional, and behavioral development at age three. 6, 7 Providing services to initiate intervention is understandably dependent on the recognition of drug-using pregnant women and exposed infants. With this in mind, states have used a variety of approaches to try to deal with the problem of drug abuse among pregnant women. Mandates differ from state to state and many states have left the screening and reporting decisions to the health provider's discretion. 8 California and Virginia passed laws to mandate hospitals to develop structured perinatal illicit drug use screening protocols (will be referred to as 'protocol' in the rest of the text). 9 Arizona, Washington, and Indiana Departments of Public Health developed detailed screening guidelines to address the perinatal drug abuse. [10] [11] [12] Currently, neither the state of Iowa nor the Iowa Department of Health has a policy for birthing hospitals to guide them in perinatal illicit drug screening. Instead, individual hospitals determine guidelines for implementing their own protocols, which are quite different from hospital to hospital. Due to a lack of consistency between hospital policies, there may be a risk of not screening all eligible infants, hence the risk of missing exposed neonates.
The purpose of this study was to evaluate the neonatal illicit drug screening practices in birthing hospitals in Iowa. We hypothesized that hospitals utilizing a structured screening protocol will have higher screening rates and higher positive test results when compared with hospitals doing arbitrary screening.
Method and subjects
A list of hospitals in Iowa where delivery services were available in year 2004 was obtained from the Iowa Hospital Association. Eighty-one birthing hospitals were identified. The total number of births in Iowa in 2004 was 37 265. 13 Each participating hospital had two or more of the following perinatal units: prenatal clinic, labor and delivery unit, newborn nursery, and newborn intensive care unit. For recruitment purposes, calls were placed to both nursing supervisors of the Department of Obstetrics and directors of Health Information and Medical Records. Fifty-three hospitals (65% of all birthing hospitals) agreed to participate. Hospital contacts were asked to identify the most appropriate individual knowledgeable about the hospital's perinatal drug screening policy. That individual was then asked to participate in a telephone interview and follow-up mailed survey.
Of the total delivery population, 25 930 (70%) were delivered in the participating hospitals. Thus, the data presented in this study is representative of 70% of infants delivered in Iowa in 2004 (Table 1) .
Of the 28 (21 Level 1, six Level 2, and one Level 3 hospital) non-participating hospitals, two (7%) refused to share any data, 14 (50%) reported they did random screening but did not track their data, 12 (43%) reported they utilized a protocol but either did not track their data or did not have sufficient human resources to participate in this study.
Data were collected using a cross-sectional survey design. Data included the hospital's screening policy, use of a structured protocol, number of inpatients and outpatients served, types of screening tests used, and numbers of screened and positive-testing neonates. The participating hospitals were divided into two groups based on whether or not they utilized a protocol. Group I consisted of those hospitals utilizing a protocol. Group II consisted of those hospitals doing arbitrary screening.
A copy of the protocol from hospitals utilizing one was obtained and reviewed regarding comprehensiveness. Characteristics that were reviewed included dates of implementation and revision, which hospital unit the protocol originated from, risk indicators for maternal and neonatal screening/testing administration, description of purpose of screening/testing, professional audience the protocol was addressed to, which hospital staff would order the screening tests, notification instructions for staff, and provision of guidelines on referral for treatment.
The data were analyzed using SPSS software program. Statistical tests used included t-tests, Mann-Whitney U, Kruskal-Wallis correlations, w 2 , and Cramer's V. An a-level of 0.05 was set for statistical significance in data analysis.
Institutional Review Board approval was not required for this research project, because no individual patient data were directly involved in the study.
Results

Description of participating hospitals
Forty-five (85%) of the 53 participant birthing hospitals reported that they were performing neonatal illicit drug screening. Thirteen participating hospitals (25%) had structured protocols that guided their screening practice (Group I). Thirty-two (60% of participating hospitals) hospitals performed screening on infants on an arbitrary basis (Group II). Eight hospitals (15%) did not perform any screening and accounted for 665 deliveries.
Of the 53 participating hospitals, 39 (74%) were Level 1 hospitals, nine (17%) were Level 2, and five (9%) were Level 3 hospitals ( Table 1) . Use of a structured protocol based on level of care is listed in Table 2 . Of the 39 Level 1 hospitals, 31 (79%) reported screening neonates for illicit drug exposure. All Level 2 and Level 3 hospitals reported they did perform neonatal screening for illicit drugs. The level of neonatal care correlated positively with the utilization of a protocol in a hospital (Mann-Whitney U-test, P<0.001).
Fifty-eight percent of hospitals that did screening tested only meconium, 13% tested only urine, and 29% tested both meconium and urine. Only 5% of hospitals reported doing hair testing on neonates to determine drug exposure in addition to a combination of the above.
Correlates of utilization of a protocol
The hospitals that utilized a protocol were located in cities with higher average city population, and higher average annual number of outpatients, inpatients, and deliveries ( Table 3) . Screening rates of individual hospitals were positively correlated with the annual number of outpatients served (r (45), P ¼ 0.012), with the annual number of inpatients served (r (45), P ¼ 0.001), with the annual number of deliveries (r (45), P ¼ 0.01), and with the level of neonatal care (r (45), P ¼ 0.01).
The hospitals in Group I reported testing 1551 infants (9.7% of total 16 007 deliveries) compared to hospitals in Group II testing 659 infants (7.1% of total 9258 deliveries), (P<0.001). However taking into consideration the hospitals' delivery sizes, Group I hospitals had an average screening rate of 10.9 per 100 births compared to 2.1 in Group II hospitals (P<0.0001). Overall, 146 infants (0.9% of total births) in Group I tested positive compared to 65 (0.7% of total births) in Group II (P ¼ 0.077). However, Group I hospitals had an average positive test rate of 0.9 per 100 births compared to 0.2 in Group II hospitals (P<0.0001). Of the screening tests that were performed in Group I hospitals, 9.4% (146/1551) were positive compared to 9.9% (65/659) in Group II hospitals (P ¼ 0.742) ( Table 4 ).
Description of protocols utilized
We obtained a copy of the protocol from 13 hospitals in Group I. All of the protocols were developed between 1997 and 2004, 46% were revised between 1999 and 2004, four protocols were revised more than once. The details covered by these protocols are outlined in Table 5 .
All protocols described risk factors indicating a need for maternal and infant screening. In fact some protocols appeared to focus mainly on outlining these risk indicators. Eight (62%) protocols detailed itemized risk factors both for the mother and the infant, whereas five (39%) protocols described categorical indicators for assessing risk, leaving the details of itemized risk factors to the discretion of the medical staff (Table 6 ). 
Access to rehabilitation services
Ninety-one percent of the hospitals surveyed reported that there was access to drug abuse rehabilitation services for the mothers in their community. Fifty-eight percent of hospitals surveyed reported in-house rehabilitation services being available to mothers with addiction problems. The availability of in-house rehabilitation services in Group I hospitals was 100% compared to 39% in Group II hospitals. Thus, the utilization of a protocol was significantly related to in-house availability of intervention services for drug rehabilitation as well (x 2 (1, n ¼ 32) ¼ 13.36, P ¼ 0.001).
Discussion
Perinatal illicit drug screening is an invaluable tool in the recognition of illicit-drug-using pregnant women and exposed infants. Although maternal interviews should be taken into careful consideration in assessing risk for perinatal illicit drug use, many studies report that the maternal interview alone cannot be relied upon to determine which families and infants need intervention for illicit drug abuse (by the mother) and exposure (for the infant), respectively. 3,14-16 However, screening certain body specimens may yield more objective information. Then the recognition of risk factors outlined by a structured protocol may help health-care providers in their decision-making as to who should be screened. These risk factors are widely reported in the literature as indicated in Table 3 . 3, 5, 11, [16] [17] [18] [19] [20] [21] It is important to recognize these factors as early in the process of pregnancy as possible since intervention can make a difference in the outcome. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] The findings in this study support the hypothesis that hospitals utilizing a protocol screen higher proportions of neonates. Positive test rate in these hospitals was also higher than the control group hospitals. In addition, the data showed that as the level of neonatal care increased so did the likelihood of utilizing a protocol.
The difference in the positive test rate may have been underestimated for the following factor. None of the birthing hospitals in Iowa has a structured in-service training procedure for the staff involved in prenatal, delivery, or neonatal care. Oral et al. 33 reported that University of Iowa Hospitals and Clinics (UIHC) long ago adopted a structured protocol. All UIHC staff is expected to follow this protocol. However, there is no structured in-service training established. Oral et al. 33 showed that 40.2% of infants delivered at the UIHC in 2002-2003 who should have been screened for illicit drugs based on risk indicators recognized by the hospital protocol were not screened. Thus, lack of a structured in-service training program may be responsible for this non-compliance with the hospital protocol. This is likely the case in all other birthing hospitals in Iowa. Thus, this may be the reason why the difference in the positive test rates are not as pronounced as expected between the two groups of hospitals.
If perinatal illicit drug exposure can be recognized early, intervention in the form of programs to improve parenting skills, maternal drug and mental health treatment, home assistance, restriction of breast feeding, and medical, developmental, and behavioral treatment services for the infant may be established. 34 It is then reasonable to expect that reduced parental drug use, in combination with post-natal interventions, may result in less chaotic lifestyles, improved care-giving, reduced numbers of child protective services interventions and foster care placements, and decreased maternal depression, hence improved outcomes for children as well. 19, 20 Response to perinatal drug use at hospital and state level As expected, hospitals with higher level of neonatal care tend to be located in urban settings with larger populations, larger numbers of outpatient and inpatient pediatric visits, and larger numbers of deliveries: these are also the hospitals with a greater likelihood of having adopted some form of a protocol. Several authors have reported that in urban, inner city, and teaching hospital settings, perinatal illicit drug exposure has been recognized by staff. This recognition prompted the establishment of a program of detection and intervention, more than is the case in rural or private health-care settings. 35, 36 In the absence of a statewide perinatal illicit drug screening policy, birthing hospitals may or may not develop structured protocols. Even if they do, these protocols may vary greatly from hospital to hospital, region to region, with regard to completeness and effectiveness. 9, 37, 38 Professionals in Iowa are well aware that pregnant women may generally prefer to obtain their prenatal care in a regional hospital, that is, a hospital where a comprehensive protocol is likely in use. However, women with risk factors for perinatal illicit drug use are observed to prefer to deliver at a neighboring hospital where there is no set policy for perinatal illicit drug screening/testing. This has been observed as a common practice in different parts of the state (personal communications with staff). In light of these observations, the advantages of establishing a statewide perinatal illicit drug screening protocol to establish a uniform standard of care are clear. 9, 29, 39 California and Virginia have already mandated that hospitals develop such structured protocols, but, unfortunately, neither state has implemented effective measures of enforcement. 9 Many states have passed laws regarding the mandated reporting of a newborn exposed to illicit drugs following Illinois and California. 9, 36, 37, 40 However, the wording in the state codes vary from state to state. For example, in Florida, a mother's report of having used illicit substances or alcohol during pregnancy is adequate evidence to file a report with child protective services. In Iowa, on the other hand, the presence of an illicit substance in a newborn's system must be documented by a laboratory test, independent of parental disclosure. Also, in Colorado, it is necessary to medically document negative fetal/ neonatal outcome related to perinatal illicit drug exposure to file a report with child protective services. 33, 36 Despite these variations, we may conclude that having statewide regulations for the detection of perinatal illicit drug exposure in place, whether through an established policy of the department of public health or direct legislation, will positively effect physician response and detection rates. 29, 38 Zellman et al. 9, 38 reported that hospitals in states with legislative regulations on perinatal illicit drug screening tend to have a protocol in place more often than the hospitals in states with no legislative mandates. Clearly, if a statewide standard of care is established, physicians and facilities become more willing to assess their patients' illicit drug or alcohol use in compliance with the statewide policy. 36 If we are to be fair and capture the majority of pregnant women using illicit drugs and newborns exposed to such, free of racial and social class biases, risk assessment must be done on objective medical and psychosocial criteria. 36 One last issue to consider is that reporting of in utero exposure to illicit drugs should in no way result in legal consequences for the mother. This approach has proven to be devastating in pregnant women's use of health services with subsequent worsening medical outcomes for both the mothers and offspring. [39] [40] [41] [42] 
Limitations
The fact that not all birthing hospitals in Iowa participated in this study is one of this study's weaknesses. At the same time, underlying reasons for those hospitals that chose not to participate in the study may be counted among the studies findings. Nonparticipating hospitals disclosed that they did not maintain an annual database to keep track of the numbers of positive neonatal drug screens. Furthermore, the hospitals responded that they could not devote the time nor staff to go back and review the charts and records to compile the requested information. Some hospitals utilized outside laboratories to maintain their database and those laboratories did not allow the researchers to access neonatal drug screening data. Thus, it appears that one-third of delivery hospitals do not recognize maintaining annual records on perinatal illicit drug screening as a priority.
Secondly, due to the limitation of the scope of the present study, we did not assess false positive and false negative rates of the screening protocols utilized or screening practice performed.
Thirdly, this study did not look at the rate of maternal screening/positive test rates, and the services provided to the mothers testing positive, a subject worthy of further investigation beyond the scope of the current work.
Lastly, this study did not survey the intervention outcomes in Iowa birthing hospitals as a result of their neonatal screening practices. Future studies would be needed not only to look at both maternal and neonatal screening/testing practices in all Iowa birthing hospitals, but also to look at the intervention outcomes following the recognition of perinatal illicit drug exposure.
Conclusion
There is great variation among the birthing hospitals of Iowa regarding diagnosis and management of perinatal illicit drug exposure. The results of this study indicate that having a structured protocol in place improves the rates of neonatal screening and positive test results. These rates are probably underestimated due to the lack of structured training of staff in those hospitals. Based on the literature reviewed here, in addition to the findings of this study, every state should consider developing uniform state guidelines for the screening, testing, and reporting of infants exposed to illicit substances in utero. The leadership role in establishing a comprehensive and uniform program will likely fall to the state's Department of Public Health. This should be followed with the development of periodic in-service training of medical staff encountering pregnant women using illicit drugs and newborns exposed to illicit drugs. Some allocation of state resources may be required to provide for training and compliance with whatever statewide measures may be developed. State agencies should collaborate with regional professional organizations such as chapters of American Academy of Pediatrics, American College of Obstetrics and Gynecology, and American Academy of Family Physicians to offer training to health-care providers to recognize illicit drug abuse. State policy-makers should create a task force with representatives drawn from various state agencies involved with provision of drug abuse treatment services to improve and allocate funding for these services.
In light of the findings of this study, a statewide collaboration has been established in Iowa to develop a consensus on perinatal screening practices, a statewide perinatal illicit drug screening policy, and an educational program to deliver periodic training to staff dealing with pregnant/delivering women and newborns in all birthing hospitals in Iowa.
